Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

June 15, 2018: By Joan McKenna

France-based Nicox has formed a research collaboration with Ironwood Pharmaceuticals that will combine Ironwood’s expertise in soluble guanylate cyclase (sGC) with Nicox’s proprietary nitric oxide (NO)-donating research platform to generate novel ophthalmic treatments.

Ironwood, of Cambridge, Massachusetts, co-markets with Allergan a product called Linzess (linaclotide), a guanylate cyclase‐C agonist to treat irritable bowel syndrome with constipation and chronic idiopathic constipation.

Under the Nicox/Ironwood collaboration, each company will be responsible for its own associated costs, and the companies may hold discussions over Nicox’ further development of any identified product candidate.

Nicox currently has two products with US approval: Vyzulta, licensed worldwide to Bausch + Lomb, and Zerviate, licensed in the US to Eyevance.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility